首页> 外文期刊>Clinical oncology >An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.
【24h】

An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.

机译:非根治性切除后食管癌术后放疗的审核。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: The role of postoperative radiotherapy (PORT) after non-curative resections for cancer oesophagus is not well defined. A policy of offering PORT after non-curative resections for cancer oesophagus has been followed at our institution, and we report an audit of our experience. MATERIAL AND METHODS: Between March 1990 and September 2002, 139 patients underwent resections for cancer oesophagus. Of these, 86 patients received PORT to a dose of 45-50.4 Gy/25-28 fractions. Eleven of these patients also received concurrent and adjuvant 5-fluorouracil (5-FU). Disease-free survival and overall survival were computed from the day of surgery using the Kaplan-Meier method. RESULTS: Seventy-six per cent (65/86) of patients had squamous cell carcinoma and 69% (59/86) of patients had tumours in the lower-third of the oesophagus. The median interval between surgery and PORT was 41 days, and 93% of patients received doses as planned. Strictures at the anastomotic site and ulcerations in the stomach mucosa were seen in 17% and 5% of patients, respectively. The median and 5-year disease-free survival was 12 months (95% CI 9.9-14.1) and 14%; whereas the median and 5-year overall survival was 17 months (95% CI 12.4-21.6) and 17%, respectively. Local and distant failures were seen in 29% and 45% of patients, respectively. CONCLUSIONS: PORT, after a non-curative resection of cancer oesophagus, is well tolerated with acceptable morbidity and survival.
机译:目的:癌症食管非根治性切除术后术后放疗的作用尚不清楚。在我们的机构中​​,我们一直遵循在癌症的非根治性切除后提供PORT的政策,并且我们报告了对我们经验的审核。材料与方法:在1990年3月至2002年9月之间,有139例因食管癌而接受了切除。其中,有86位患者接受PORT的剂量为45-50.4 Gy / 25-28分数。这些患者中有11名同时接受了辅助和5-氟尿嘧啶(5-FU)治疗。使用Kaplan-Meier方法从手术当天算起无病生存期和总生存期。结果:百分之七十六(65/86)的患者患有鳞状细胞癌,而百分之六十九(59/86)的患者在食管的下三分之一中具有肿瘤。手术和PORT之间的中位间隔为41天,并且93%的患者按计划接受剂量。分别在17%和5%的患者中看到吻合口处的狭窄和胃粘膜的溃疡。中位和5年无病生存期分别为12个月(95%CI 9.9-14.1)和14%;而中位生存期和5年总生存期分别为17个月(95%CI 12.4-21.6)和17%。分别有29%和45%的患者出现局部和远距离衰竭。结论:非治疗性食管癌切除后的PORT耐受性良好,发病率和生存率均可接受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号